

Resource Summary Report

Generated by [NIF](#) on Aug 25, 2026

PerCP/Cyanine5.5 anti-mouse CD4

RRID:AB_893326

Type: Antibody

Proper Citation

BioLegend Cat# 100540, RRID:AB_893326

Antibody Information

URL: http://antibodyregistry.org/AB_893326

Proper Citation: BioLegend Cat# 100540, RRID:AB_893326

Target Antigen: CD4

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-mouse CD4

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: Clone RM4-5

Antibody ID: AB_893326

Vendor: BioLegend

Catalog Number: 100540

Alternative Catalog Numbers: 100539

Record Creation Time: 20250820T004450+0000

Record Last Update: 20250820T090521+0000

Ratings and Alerts

No rating or validation information has been found for PerCP/Cyanine5.5 anti-mouse CD4.

No alerts have been found for PerCP/Cyanine5.5 anti-mouse CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 45 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Guo J, et al. (2026) VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment. Cancer immunology research, 14(5), 718.

Fukugaki A, et al. (2026) Enhancing Immunotherapeutic Response in Colorectal Cancer with a Neuropilin 1-Targeting Tumor-Penetrating Peptide. Cancer research communications, 6(6), 1364.

Liu Y, et al. (2026) Immunogenic tumor cell death and T-cell-derived IFN- γ elicit tumoricidal macrophages to potentiate OX40 immunotherapy. Cell reports. Medicine, 7(4), 102699.

Murakami R, et al. (2026) Foxp3 and BATF cooperatively direct cis-regulatory programs and gene expression for effector Treg cell differentiation. Immunity, 59(5), 1253.

Castaño D, et al. (2025) Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses. Cell, 188(26), 7461.

Peng X, et al. (2025) Virus envelope glycoprotein targeting bispecific T cell engager protects mice from lethal severe fever with thrombocytopenia virus infection. Cell reports. Medicine, 6(11), 102458.

Köhne M, et al. (2025) Satb1 directs the differentiation of TH17 cells through suppression of IL-2 expression. Cell reports, 44(7), 115866.

Fan Q, et al. (2025) Hepatic Lamp2a deficiency promotes inflammation of murine autoimmune cholangitis via affecting bile acid metabolism. iScience, 28(2), 111804.

Wang W, et al. (2025) BET inhibitor in combination with BCG vaccine enhances antitumor efficacy and orchestrates T cell reprogramming for melanoma. Cell reports. Medicine, 6(3), 101995.

Zhou RW, et al. (2025) Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens. Cell.

Lubosch A, et al. (2025) The immune response against cancer is modulated by stromal cell fibronectin. *Neoplasia* (New York, N.Y.), 67, 101196.

Patel E, et al. (2024) XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies. *Molecular cancer therapeutics*, 23(4), 421.

Sun X, et al. (2024) Deletion of the mRNA endonuclease Regnase-1 promotes NK cell anti-tumor activity via OCT2-dependent transcription of *Ifng*. *Immunity*, 57(6), 1360.

Xie MM, et al. (2023) An agonistic anti-signal regulatory protein γ antibody for chronic inflammatory diseases. *Cell reports. Medicine*, 4(8), 101130.

Kafai NM, et al. (2023) Entry receptor LDLRAD3 is required for Venezuelan equine encephalitis virus peripheral infection and neurotropism leading to pathogenesis in mice. *Cell reports*, 42(8), 112946.

Azizov V, et al. (2023) Alcohol-sourced acetate impairs T cell function by promoting cortactin acetylation. *iScience*, 26(7), 107230.

Lu J, et al. (2023) Five Inhibitory Receptors Display Distinct Vesicular Distributions in Murine T Cells. *Cells*, 12(21).

Zhang Z, et al. (2023) Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies. *Cell reports. Medicine*, 4(12), 101336.

Florian DC, et al. (2023) Nanoparticle STING Agonist Reprograms the Bone Marrow to an Antitumor Phenotype and Protects Against Bone Destruction. *Cancer research communications*, 3(2), 223.

Leca J, et al. (2023) IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment. *Cancer cell*, 41(2), 323.